Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. (2018). SKIN The Journal of Cutaneous Medicine, 2(S1), S10. https://doi.org/10.25251/skin.2.supp.10